Nanog Inhibitors
The class of Nanog inhibitors encompasses a diverse array of chemical compounds designed to modulate the activity of Nanog, a pivotal transcription factor crucial for maintaining pluripotency in embryonic stem cells. While direct inhibitors of Nanog are limited, researchers have identified chemicals that, through their actions on specific signaling pathways, epigenetic regulators, or cellular processes, can influence Nanog expression indirectly. One notable group of Nanog inhibitors includes compounds that target the RhoA/ROCK pathway. Fasudil and Y-27632, both inhibitors of Rho-associated protein kinase (ROCK), modulate cytoskeletal dynamics and downstream signaling pathways related to stem cell pluripotency. Epigenetic regulation plays a crucial role in controlling Nanog expression, and BET inhibitors like I-BET151 and JQ1 offer a pharmacological avenue to explore this aspect. These compounds selectively target bromodomain-containing proteins, influencing chromatin accessibility and, consequently, the transcriptional regulation of Nanog.
Modulation of the Wnt/β-catenin pathway represents another strategy to influence Nanog expression indirectly. CHIR99021, XAV939, and Wnt-C59, inhibitors of GSK-3, tankyrase, and porcupine, respectively, disrupt Wnt signaling cascades. The class of Nanog inhibitors also includes compounds targeting BMP signaling, such as LDN-193189 and Dorsomorphin. These inhibitors influence cellular processes related to pluripotency and may indirectly impact Nanog expression by modulating BMP signaling, contributing to a deeper understanding of the interconnected signaling pathways governing Nanog. Furthermore, tyrosine kinase inhibitors like Nintedanib, with broad-spectrum activity against receptors in various signaling pathways, provide researchers with a tool to investigate the complex interplay between these pathways and Nanog-mediated stem cell functions. While direct Nanog inhibitors are limited, the diversity within this chemical class allows researchers to explore the nuanced regulatory networks controlling Nanog in different cellular contexts. These pharmacological tools contribute to advancing our understanding of pluripotency maintenance and the intricate molecular mechanisms governing Nanog in embryonic stem cells.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
I-BET 151 Hydrochloride | 1300031-49-5 (non HCl Salt) | sc-391115 | 10 mg | $450.00 | 2 | |
I-BET151 is a selective inhibitor of bromodomain and extra-terminal (BET) proteins. It influences the epigenetic regulation of gene expression by targeting the bromodomains of BET proteins, which can indirectly impact Nanog expression. As BET proteins play a role in chromatin remodeling, I-BET151 disrupts the interactions between BET proteins and chromatin, potentially influencing the accessibility of the Nanog gene locus and its transcriptional regulation. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1 is another BET inhibitor that selectively targets bromodomain-containing proteins. Similar to I-BET151, JQ1 modulates the epigenetic landscape by disrupting the interactions between BET proteins and chromatin. By interfering with the chromatin accessibility, JQ1 can indirectly impact Nanog expression, providing a pharmacological avenue to investigate the epigenetic regulation of Nanog and its role in stem cell pluripotency. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a selective inhibitor of Rho-associated protein kinase (ROCK). By inhibiting ROCK, Y-27632 influences cellular processes related to stem cell pluripotency, potentially impacting Nanog indirectly. The inhibition of ROCK alters cytoskeletal dynamics and downstream signaling pathways that regulate Nanog expression and function. | ||||||
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline | 1062368-24-4 | sc-476297 | 5 mg | $240.00 | ||
LDN-193189 is a chemical inhibitor that selectively targets BMP type I receptors, including ALK2 and ALK3. By inhibiting BMP signaling, LDN-193189 influences cellular processes related to pluripotency and may indirectly impact Nanog expression. BMP signaling has been implicated in the regulation of Nanog levels, and LDN-193189 serves as a tool to explore the interplay between BMP signaling and Nanog-mediated stem cell functions. | ||||||
Wnt-C59 | 1243243-89-1 | sc-475634 sc-475634A sc-475634B | 5 mg 10 mg 50 mg | $214.00 $326.00 $1275.00 | 1 | |
Wnt-C59 is a chemical inhibitor of porcupine, a membrane-bound O-acyltransferase involved in Wnt ligand secretion. By inhibiting porcupine, Wnt-C59 disrupts Wnt secretion and impairs Wnt signaling. As Wnt signaling can influence Nanog expression, Wnt-C59 may indirectly modulate Nanog levels by affecting the transcriptional activity of the Wnt pathway. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin is an AMP-activated protein kinase (AMPK) inhibitor that impacts the BMP signaling pathway. By inhibiting AMPK, Dorsomorphin disrupts BMP signaling, potentially influencing Nanog expression indirectly. BMP signaling has been linked to the regulation of Nanog levels, and Dorsomorphin serves as a pharmacological tool for researchers to investigate the crosstalk between AMPK signaling, BMP signaling, and Nanog-mediated stem cell functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK). Its action on JNK influences cellular processes related to pluripotency, potentially impacting Nanog indirectly. JNK signaling has been implicated in the regulation of Nanog expression, and SP600125 serves as a pharmacological tool for researchers to explore the intricate connections between JNK signaling and Nanog-mediated stem cell functions. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 is a selective inhibitor of the TGF-β type I receptor ALK5. By inhibiting ALK5, SB431542 disrupts the canonical TGF-β signaling pathway, potentially influencing Nanog activity indirectly. TGF-β signaling has been linked to the regulation of Nanog levels. | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $184.00 $321.00 | 2 | |
Nintedanib is a tyrosine kinase inhibitor that targets receptors involved in signaling pathways such as VEGFR, PDGFR, and FGFR. Its broad-spectrum inhibition of tyrosine kinases influences cellular processes related to pluripotency and may indirectly impact Nanog expression. | ||||||